Further studies on pituitary and ovarian function in women receiving hormonal contraception

Brian L. Cohen, Maurice Katz

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

Pituitary and ovarian function was evaluated in women receiving 3 combined oral contraceptive preparations. Basal levels of follicle stimulating hormone (FSH) and luteinizing hormone (LH) and gonadotropic responses to gonadotropic releasing hormone (GnRH) were studied in 36 healthy, regularly ovulating women in the early follicular and mid-luteal phases of their menstrual cycle (non-treatment, control). These same women were then divided into 3 groups with 12 volunteers in each. Each group received an oral contraceptive preparation cyclically for 3 months. The preparations were: Nordette (30μg ethinyl estradiol and 150 μg d-norgestrel), Nordiol (50μg ethinyl estradiol and 250μg d-norgestrel) and Biphasil (50μg ethinyl estradiol and 50μg d-norgestrel × 11 days and 125μg d-norgestrel × 10 days). In the third month of treatment, the tests were repeated on day 21, i.e. after 21 active pills, and on day 28, i.e. after 21 active and 7 inactive tablets. On active therapy, basal FSH and LH were similarly suppressed in the 3 groups. LH had varied responses to a bolus of GnRH, whilst the FSH responses were similar in the 3 groups. After 7 days of inactive tablets, basal FSH and LH had returned to pre-treatment, early follicular phase levels. However, the LH responses to a bolus of GnRH varied in the 3 groups, but again, no differences were noted in the FSH responses. Basal FSH, LH and E2 recovered earlier in the Nordette group during the 7 days of inactive tablets.

Original languageEnglish (US)
Pages (from-to)159-172
Number of pages14
JournalContraception
Volume24
Issue number2
DOIs
StatePublished - Aug 1981
Externally publishedYes

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology

Fingerprint

Dive into the research topics of 'Further studies on pituitary and ovarian function in women receiving hormonal contraception'. Together they form a unique fingerprint.

Cite this